Skylight Investment
Skylight Investment is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Skylight Investment.
Skylight Investment is a company.
Key people at Skylight Investment.
Key people at Skylight Investment.
Skylight Investment is a venture capital firm based in Boston, Massachusetts (with references to Brookline), founded in 2016, that invests in early-stage startups with disruptive technologies.[1][2][3] Its mission centers on backing companies in sectors like technology, Internet of Things (IoT), SaaS, FinTech, Artificial Intelligence & Machine Learning, Life Sciences, Robotics and Drones, biotechnology, hardware, blockchain, transportation, tourism, and novel materials, with a portfolio skewed toward therapeutics, medical devices, wellness, and personal health in the US.[1][2][3][5] The firm typically targets startups valued at $5-10 million, invests in deals of $5-10 million, and participates in fewer than 2 deals per year, with peak activity in 2018 and notable investments like Tivic Health.[2] Its investment philosophy emphasizes excellent teams and disruptive tech in early stages (seed, early VC, later VC), contributing to the startup ecosystem through selective support for 2-3 year-old companies, primarily in the US.[1][2][3]
Skylight Investment was established in 2016 as a VC fund in North America, specifically in the United States, with its main office in Brookline near Boston.[2] Limited public details exist on key partners or founders, but the firm quickly focused on early-stage investments in high-tech sectors, aligning its location with its primary investment geography in the US.[2] Its evolution shows consistent but low-volume activity—around 8 total investments, 1 round per year on average, and a follow-on index of 0.25—with heightened deal flow in 2019 and peak in 2018, including portfolio companies like Tivic Health in wellness and CRM-related areas.[2] This trajectory reflects a deliberate, niche approach rather than rapid expansion.
Skylight Investment rides trends in AI, robotics, biotech, and blockchain, sectors experiencing explosive growth due to advancements in automation, personalized medicine, and decentralized finance.[1][3][5] Its timing since 2016 aligns with the post-2015 AI boom and biotech funding surge, amplified by market forces like increased VC inflows into US health tech (e.g., therapeutics and medical devices comprising much of its portfolio).[2] By selectively funding early-stage disruptors, it influences the ecosystem through capital for 2-3 year-old startups, helping bridge seed to growth amid competition from larger funds; its US focus leverages America's dominance in these fields.[2]
Skylight Investment's low-volume, high-conviction model positions it well for continued niche impact in AI-biotech intersections and Web3 hardware, especially as 2025 trends like AI-driven drug discovery and robotics scale.[1][2][5] Upcoming deals may rise with maturing portfolios (e.g., follow-ons at 0.25 index), shaped by regulatory tailwinds in FinTech/blockchain and US innovation hubs.[2] Its influence could evolve toward more therapeutics/wellness plays, amplifying early-stage momentum in a consolidating VC landscape—echoing its founding bet on disruptive teams to sustain long-term ecosystem contributions.[2][3]
